Datapoint: FDA Approves Biogen’s Lucentis Biosimilar

The FDA on Monday approved Biogen and Samsung Bioepis’ Byooviz, a biosimilar to Roche’s blockbuster eye drug Lucentis. The approval marks Samsung Bioepis’ fifth biosimilar win. For the treatment of age-related macular degeneration, Lucentis holds covered or better status for 49% of all insured lives under the pharmacy benefit. It is not covered for 30.6% of lives.

SOURCE: MMIT Analytics, as of 9/22/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 6

Datapoint: Moda Health to Expand to Idaho

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 5

Datapoint: North Carolina Delays Launch of New Medicaid MCOs

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 4

Datapoint: FDA Approves Avastin Biosimilar

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today